Business Wire

Semperis Enhances the Industry’s Most Comprehensive Active Directory Protection Platform with Continuous Security Validation

4.5.2021 16:00:00 EEST | Business Wire | Press release

Share

Semperis, the pioneer of identity-driven cyber resilience for enterprises, today announced the general availability of Directory Services Protector (DSP) v3.5, which includes DSP Intelligence, a new module that provides automated security assessments of Microsoft Active Directory (AD). DSP Intelligence proactively uncovers dangerous vulnerabilities that arise from external threat actors, systemic weaknesses in default identity and access settings, and even internal configuration drift that leads to security regression.

The company also announced enhancements to Active Directory Forest Recovery (ADFR), the only disaster recovery product for AD purpose-built to combat cyberattacks. New ADFR capabilities include unique backup set encryption keys, advanced forensics search, and extended support for SAML and MFA authentication.

The continuous security assessment capabilities now available in DSP Intelligence address the skyrocketing proliferation of cyberattacks—including the infamous SolarWinds supply-chain attack and the Hafnium attack on Microsoft Exchange—that target identity systems, especially AD. As the gatekeeper to critical applications and data in 90% of organizations worldwide, AD is a common access vector for attackers and extremely complex to secure given its constant flux, sheer number of settings, and the increasingly sophisticated threat landscape. Findings from companies using Semperis’ free Purple Knight security assessment tool revealed that even large organizations with significant investments in security resources are failing to close critical gaps in AD, scoring an average of 61%, with Kerberos authentication being the top risk area.

“Active Directory is a critical piece of most enterprises’ IT infrastructure but is notoriously difficult to keep secure,” said Darren Mar-Elia, Vice President of Products at Semperis. “Not only are its settings complex, but both AD itself and attack paths are constantly evolving. Organizations must be able to ensure their directory services are secure on a continual basis—not just at a point in time—while actively testing against the latest indicators for new attacks and threats. DSP Intelligence is designed to provide a larger range of security indicators and advance pre-attack tests to harden AD against new adversary TTPs and spot your weaknesses before attackers do. The threat hunting capabilities have also proven to be extremely helpful for organizations in post-breach scenarios to understand how attackers broke in and how to close backdoors for good.”

A growing number of breaches involve the exploitation of suboptimal AD configurations to allow attackers to gain a foothold within target networks, access sensitive resources, and deploy malware. To get ahead of attackers, DSP Intelligence continuously queries an organization’s AD environment and performs a comprehensive set of tests against the most common and effective attack vectors that correlate to known security frameworks such as the MITRE ATT&CK.

With the addition of DSP Intelligence, Semperis further establishes DSP as the industry’s most comprehensive AD threat detection and response platform. Semperis also updated the complementary modules, DSP Essential and DSP Advanced, which address foundational directory security and operational use cases:

  • DSP Essential– AD change tracking and rollback
  • DSP Advanced– Autonomous threat protection and response
  • DSP Intelligence – Security validation and breach prevention

To see DSP Intelligence in action, watch the five-minute video overview: https://pages.semperis.com/dsp-intelligence-video-intro/

For more information about DSP and ADFR, visit the product pages below:

About Semperis

For security teams charged with defending hybrid and multi-cloud environments, Semperis ensures integrity and availability of critical enterprise directory services at every step in the cyber kill chain and cuts recovery time by 90%. Purpose-built for securing Active Directory, Semperis’ patented technology protects over 40 million identities from cyberattacks, data breaches, and operational errors. The world’s leading organizations trust Semperis to spot directory vulnerabilities, intercept cyberattacks in progress, and quickly recover from ransomware and other data integrity emergencies. Semperis is headquartered in New Jersey and operates internationally, with its research and development team distributed between San Francisco and Tel Aviv.

Semperis hosts the award-winning Hybrid Identity Protection conference (www.hipconf.com). The company has received the highest level of industry accolades and was recently ranked the fourth fastest-growing company in the tri-state area and 35th overall in Deloitte’s 2020 Technology Fast 500™. Semperis is accredited by Microsoft and recognized by Gartner.

Twitter https://twitter.com/SemperisTech
LinkedIn https://www.linkedin.com/company/semperis
Facebook https://www.facebook.com/SemperisTech
YouTube https://www.youtube.com/channel/UCycrWXhxOTaUQ0sidlyN9SA

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Media Contact
Jessica MacGregor
fama PR for Semperis
Semperis@famapr.com
617-986-5024

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Bial Announces Completion of Phase 2b ACTIVATE Study with BIA 28-6156 in GBA1-Associated Parkinson’s26.5.2026 09:00:00 EEST | Press release

Bial, an innovation-driven biopharmaceutical company focused on neurosciences and rare diseases, today announced the completion of the treatment period in its Phase 2b ACTIVATE study of BIA 28-6156 (pariceract) in patients with Parkinson’s disease (PD) who have a pathogenic mutation in the glucocerebrosidase 1 (GBA1) gene (GBA-PD). Upon completion of the 78-week double-blind treatment period and all scheduled safety follow-ups, data cleaning and analysis are currently ongoing. Topline results will be released around the end of Q2. A status report on the ACTIVATE study was presented in an oral presentation at the 3rd International GBA1 Meeting 2026. The team is currently attending the 7th World Parkinson Congress, taking place in Phoenix from 24 to 27 May 2026. “Momentum is building across the Parkinson’s scientific community around the clinical potential of pariceract. At the GBA1 Meeting and the 7th World Parkinson Congress, we have been able to connect with this community as we appro

Oticon Medical Introduces Ponto™ Instant, Expanding Non-Surgical Choice with Instant HearBand and Instant SoundConnector26.5.2026 08:00:00 EEST | Press release

Oticon Medical today announces its new non-surgical portfolio, Ponto Instant, designed to broaden access to bone conduction hearing and offer more choice for users and hearing care professionals. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260525771593/en/ Left: Instant HearBand, a discreet behind-the-head wearable solution that offers an alternative to Softband 5. Right: Instant SoundConnector, a small accessory fitted to a cap or other headwear, providing another non-surgical way to wear a Ponto sound processor. The Ponto Instant portfolio includes Softband 5, Oticon Medical’s established and trusted non-surgical solution, and now expands with the launch of Instant HearBand and Instant SoundConnector, further strengthening its wearable offering for children and adults who prefer a non-surgical solution. Instant HearBand: a discreet new wearable alternative As part of the new portfolio, Instant HearBand is introduced as

Barilla Opens Global Call for Startups Through Good Food Makers 202625.5.2026 12:47:00 EEST | Press release

Barilla Group has opened applications for the 2026 edition of Good Food Makers, its global open innovation program designed to co-develop and test new innovative solutions with startups and innovators inside real industrial environments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521973445/en/ Since its launch in 2019, the program has involved more than 1,100 startups from over 50 countries, leading to 26 pilot projects, with over 20 projects currently active thanks to the solutions developed by the program’s alumni. This highlights the program’s role as a concrete platform for industrial scalable innovation. The 2026 edition comes at a pivotal moment for the company, following the launch of BITE (Barilla Innovation & Technology Experience), the new innovation center dedicated to developing the next generation of food products. Within this inspiring premise, Good Food Makers confirms itself as one of the main levers f

JEOL: Sales Launch of the Laser SEM System “LazEdge”25.5.2026 11:16:00 EEST | Press release

JEOL Ltd. (President & CEO: Izumi Oi) has developed the “LazEdge”, an SEM system equipped with a laser processing system, and begins sales on May 25, 2026. Cross-section preparation instruments such as the focused ion beam system (FIB system), are widely used in science and technology fields across research institutes, universities, and industries. In recent years, demand is increasing for a system that can process large-areas at a high speed, while achieving high-quality of the processed surface. “LazEdge” is an instrument integrating JEOL’s SEM with the laser technology proprietary of Hamamatsu Photonics K.K., and enables laser processing inside the specimen chamber of the electron microscope. This system enables high-quality cross-section specimens produced through high-speed, large-area processing to be transferred seamlessly to subsequent analyses, such as SEM observation, elemental analysis, and crystal orientation analysis, without exposure to the external environment. As a resu

TFG-001, A Novel 3D Neural Microtissue Cell Therapy, Demonstrates Superior Functionality and Reinnervation for Parkinson’s Disease25.5.2026 09:00:00 EEST | Press release

TreeFrog Therapeutics, a regenerative medicine biotech company developing next-generation cell therapies, today announced that it will present new preclinical data on TFG-001 at the 7th World Parkinson’s Conference. TFG-001, a 3D neural microtissue cell therapy, demonstrated rapid dopamine release and extensive graft-derived reinnervation across multiple advanced translational Parkinson’s disease models—supporting its potential as a best-in-class candidate. The critical need for reinnervation in Parkinson's disease In Parkinson's disease, an estimated 60–80% of dopaminergic neurons are already lost before motor symptoms even appear. The nigrostriatal pathway degenerates, destroying the essential wiring that connects dopamine-producing neurons to movement control. While chemical dopamine replacements (like levodopa) can manage symptoms, they cannot restore the spatial precision, feedback loops, or dynamic regulation of a healthy brain network. To achieve true functional restoration, it

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye